{"id":"W3087842901","doi":"10.1016/j.annonc.2020.08.438","title":"336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"EMD Serono; Genentech; PharmaMar; Springworks Therapeutics; MacroGenics; Silverback Therapeutics; Cilag; Puma Biotechnology; Relay Therapeutics; Eisai; Celltrion; Syndax Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Unum Therapeutics; Amgen; Radius Health; Clovis Oncology; Les Laboratories Pierre Fabre; Genomic Health; Ipsen; Array BioPharma; Mersana Therapeutics; Karyopharm Therapeutics; NuCana; Pfizer; Incyte; Taiho Pharmaceutical; F. Hoffmann-La Roche; GlaxoSmithKline; Jounce Therapeutics; PTC Therapeutics; Celgene; Cancer Research Institute; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Sanofi","keywords":"Medicine; Palbociclib; Breast cancer; Internal medicine; Fulvestrant; Oncology; Cancer; Estrogen receptor; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008945236,0.0008920953,0.001246644,0.0004818793,0.00028622,0.001088413,0.0005663284,0.0008535311,0.002242224],"category_scores_gemma":[0.0005603718,0.0003552504,0.0009356314,0.0004598441,0.0006371842,0.0004788899,0.0003303117,0.002060239,0.0006953057],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082277,"about_ca_system_score_gemma":0.001149867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001103675,"about_ca_topic_score_gemma":0.003641687,"domain_scores_codex":[0.9997643,0.00007008132,0.00001265614,0.00003899355,0.00004508852,0.00006895362],"domain_scores_gemma":[0.9997506,0.00003281616,0.00003602724,0.0000220295,0.00003122075,0.0001273979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.579472,0.04271878,0.07854933,0.0009666448,0.003523446,0.0004729429,0.0003030126,0.004518944,0.08413883,0.0005194534,0.007947871,0.1968687],"study_design_scores_gemma":[0.2896274,0.423009,0.2337629,0.0001457085,0.004509099,0.001218344,0.0003826974,0.0063102,0.02564023,0.0007485212,0.01449754,0.0001482681],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963168,0.00145541,0.00008899229,0.0002923466,0.00005582938,0.0003367866,0.0006180848,0.00002835324,0.0008074171],"genre_scores_gemma":[0.9930115,0.001144776,0.0005699696,0.0005973708,0.00005494991,0.0004975589,0.002333793,0.00001718671,0.001772904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002242224,"threshold_uncertainty_score":0.007852435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09332269885895235,"score_gpt":0.4520226320281667,"score_spread":0.3586999331692143,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}